一级创伤、综合卒中中心夜间急诊药师实施的成本规避
该研究回顾性评估了2020年11月25日至2021年3月12日期间,在一级创伤、综合卒中中心扩大急诊服务时段(2300-0700)配备夜间急诊药师(EMP)所记录临床干预的成本规避。EMP可从45项与成本规避相关的临床患者照护建议中选择并记录干预,每位患者允许记录多项干预,但同一临床干预不能重复计数;记录的干预依据现有评估药学临床干预的文献赋予货币成本规避值。研究还比较了有、无EMP时从影像到全身溶栓的时间及达到door-to-alteplase(入院至阿替普酶)基准的患者百分比。结果显示,夜间EMP在107个夜班中记录820项干预,成本规避612,974美元;最常见干预为床旁监测(n=127;50,694美元)、药物信息咨询(97;11,269美元)和抗菌治疗启动与优化(95;60,101美元)。按类别分,378项(46%;292,484美元)为直接照护,216项(26%;94,899美元)为个体化患者照护,135项(17%;25,897美元)为行政与支持任务,84项(10%;121,746美元)为药物不良事件预防,7项(1%;77,964美元)为资源利用。评估期间所有急性缺血性卒中患者(n=6)在有EMP时均≤45分钟接受全身溶栓,而无EMP时50%在≤45分钟内接受溶栓。结论认为,扩大夜间EMP覆盖为危重患者提供了此前研究实施前无法获得的临床床旁药物治疗专业知识,临床干预与显
要点
- 夜间EMP在107个夜班中记录820项干预,成本规避612,974美元。
- 最常见干预为床旁监测(n=127;50,694美元)、药物信息咨询(97;11,269美元)、抗菌治疗启动与优化(95;60,101美元)。
- 干预分类:直接照护378项(46%;292,484美元)、个体化患者照护216项(26%;94,899美元)、行政与支持任务135项(17%;25,897美元)、药物不良事件预防84项(10%;121,746美元)、资源利用7项(1%;77,964美元)。
- 评估期间6例急性缺血性卒中患者在有EMP时均≤45分钟接受全身溶栓,无EMP时50%在≤45分钟内接受溶栓。
- 结论认为扩大夜间EMP覆盖为危重患者提供床旁药物治疗专业知识,临床干预与显著成本规避相关。
适用人群与场景
- 一级创伤、综合卒中中心,扩大急诊服务时段(2300-0700)的夜间急诊患者,包括危重患者和急性缺血性卒中患者。
研究设计与关键结果
- 研究类型:回顾性评估前瞻性跟踪的干预,单中心一级创伤、综合卒中中心,时间2020年11月25日至2021年3月12日,扩大急诊服务时段(2300-0700)。
- 干预:EMP可从45项与成本规避相关的临床患者照护建议中选择并记录干预;每位患者允许记录多项干预,但同一临床干预不能重复计数;记录的干预依据现有评估药学临床干预的文献赋予货币成本规避值。
- 主要结果:夜间EMP在107个夜班中记录820项干预,成本规避612,974美元。
- 最常见干预:床旁监测(n=127;50,694美元)、药物信息咨询(97;11,269美元)、抗菌治疗启动与优化(95;60,101美元)。
- 干预分类:直接照护378项(46%;292,484美元)、个体化患者照护216项(26%;94,899美元)、行政与支持任务135项(17%;25,897美元)、药物不良事件预防84项(10%;121,746美元)、资源利用7项(1%;77,964美元)。
- 卒中时间指标:评估期间所有急性缺血性卒中患者(n=6)在有EMP时均≤45分钟接受全身溶栓,而无EMP时50%在≤45分钟内接受溶栓。
证据类型、等级与局限
- 证据类型:回顾性评估前瞻性跟踪的干预,单中心。
- 局限:原文未报告局限性。
对床旁实践的改变
- 扩大夜间EMP覆盖可为危重患者提供床旁药物治疗专业知识,这些专业知识在研究实施前无法获得(作者结论)。
- EMP记录的临床干预与显著成本规避相关(作者结论)。
- 有EMP时,评估期间所有急性缺血性卒中患者(n=6)均≤45分钟接受全身溶栓,而无EMP时50%在≤45分钟内接受溶栓。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To investigate the cost-avoidance associated with implementation of an overnight emergency medicine pharmacist (EMP) through documented clinical interventions.
DESIGN: Retrospective evaluation of prospectively tracked interventions in a single Level I Trauma, Comprehensive Stroke Center, from November 25, 2020 through March 12, 2021 during expanded emergency medicine service hours (2300-0700).
INTERVENTIONS: One of 45 clinical patient-care recommendations associated with cost-avoidance were available to be selected and documented by the EMP; more than one intervention was allowed per patient, though one clinical intervention could not be counted as multiple items. Documented services were associated with monetary cost avoidance based upon available literature assessing pharmacy clinical interventions. Differences in time from imaging to systemic thrombolytics and percentage of patients meeting door-to-alteplase benchmarks were compared with and without the availability of EMPs.
RESULTS: Overnight EMPs documented 820 interventions during 107 overnight shifts with a cost avoidance of $612,974. The most common interventions were bedside monitoring (n = 127; $50,694), drug information consultation (97; $11,269), and antimicrobial therapy initiation and streamlining (95; $60,101). When categorizing interventions, 378 (46%; $292,484) were input as hands-on care, 216 (26%; $94,899) as individualization of patient care, 135 (17%; $25,897) as administrative and supportive tasks, 84 (10%; $121,746) as adverse drug event prevention, and 7 (1%; $77,964) as resource utilization. All patients (n = 6) with an acute ischemic stroke during the evaluation period received systemic thrombolytics ≤45 min in the presence of EMPs compared with 50% receiving thrombolytics ≤45 min without EMPs.
CONCLUSIONS: Expanded overnight coverage by EMPs provided clinical bedside pharmacotherapy expertise to critically ill patients otherwise not available prior to study implementation. Clinical interventions were associated with substantial cost-avoidance.
参考来源
- Nguyen MH, Gordon K, Reachi B, et al. Cost-avoidance associated with implementation of an overnight emergency medicine pharmacist at a Level I Trauma, Comprehensive Stroke Center. Am J Emerg Med. 2024. PMID: 38805940. doi:10.1016/j.ajem.2024.05.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。